Alpha Lipoic Acid

Story at a glance

Alpha Lipoic Acid

Alpha lipoic acid (ALA) is a sulfur-containing fatty acid compound that is naturally produced by plants and animals. In humans, it is synthesized in the mitochondria, where it functions as an essential cofactor for enzymes that participate in mitochondrial energy metabolism. However, when ALA is ingested from dietary sources, instead of functioning as an enzyme cofactor it appears to have a broader range of effects and a therapeutic potential for treating conditions such as neurodegenerative, auto-immune, and cardiovascular issues as well as liver regeneration and CFCs.

In a cell, ALA is reduced to dihydrolipoic acid (DHLA), which acts as a potent antioxidant and therefore modulates oxidative stress and inflammatory pathways. Studies done with ALA have revealed several effects that can be used to eliminate CFCs by targeting metabolic pathways essential and specific for them and to support healthy body functions of the person treated. Some of the benefits of ALA are:

Supporting Antioxidative and Detoxification Processes

ALA has been found to reduce oxidative stress by restoring levels of antioxidants such as vitamin C and glutathione and chelating metals and removing them from blood. ALA also enhances the production of phase II detoxifying enzymes such as glutathione S-transferases and NAD(P)H: quinone oxidoreductase which are specialized for neutralizing a variety of carcinogenic compounds that can eventually lead to the development of CFCs. ALA induces synthesis of the enzymes by activating a transcription factor Nrf2 (nuclear factor erythroid 2-related factor 2). Nrf2 binds to the antioxidant response element (ARE) which in turn activates the expression of genes for phase II enzymes. Experimental studies on mice have demonstrated the necessity of these enzymes in preventing the formation of CFCs since mice lacking Nfr2 activity are unable to produce these enzymes in response to carcinogens and consequently develop CFCs significantly more often. 

ALA can prevent the formation and accumulation of advanced glycation (adding sugar) end products (AGEs). AGEs are formed in protein glycation, also known as the Maillard reaction, which is a complex chemical reaction between reducing sugars and amino acids of proteins. This process occurs in the body but AGEs can also be ingested from dietary sources, especially from foods cooked in high temperatures. AGEs are a significant source of oxidative damage in the body as they accumulate in tissues and generate ‘free radicals’ or what are known as reactive oxygen species (ROS). They also bind to a receptor called receptor for advanced glycation end products (RAGE) which triggers signaling pathways that lead to activation of NF-κB that drives major processes in CFC formation and progression. Excessive formation of AGEs and their accumulation in various tissues is associated with the development of chronic conditions such as diabetes and CFCs in humans.

Improving Blood Sugar Levels

Studies on people with type 2 diabetes have shown that ALA treatment can reduce serum lactate and pyruvate levels and improve glucose effectiveness. Lactate is the end product of fermentation and pyruvate is what glucose becomes once it enters a cell. One mechanism by which ALA may achieve this is by enhancing glucose uptake by the cell, achieved by increasing the number of glucose transporters on the cell membranes in the muscle and liver. This is essentially linked to CFCs since elevated levels of glucose and lactate in blood since one is required as a primary energy source for the growth of CFCs and the other is the end-product of glucose fermentation.

ALA has been shown to improve insulin sensitivity also by activating an enzyme called AMP-activated protein kinase (AMPK). AMPK functions as a sensor for fuel in a cell and is normally activated when the cellular energy (ATP) is depleted. Activated AMPK increases glucose uptake, fatty acid oxidation, and mitochondrial biogenesis. The blood glucose level is largely regulated by skeletal muscle tissue and lipid (fat) accumulation in muscle cells weakens insulin signaling of muscle cells and insulin resistance of the whole body. Activation of AMPK by ALA reduces lipid accumulation in skeletal muscles.

Alleviating Symptoms Caused by Conventional Treatments 

ALA has been found to be effective in reducing neuropathy (nerve pain) symptoms caused by chemotherapy. One of the most harmful effects that CFCs and conventional treatments cause is muscle and tissue wasting. This largely results from raised levels of proinflammatory cytokines and high energy demands of CFCs. Inflammation and weight loss due to tissue wasting have been found to correlate with CFC progression in people. Studies have shown that treating people suffering from CFCs with ALA can reduce pro-inflammatory cytokines IL-6 and TNFα and restore T cell function.

Targeting and Eliminating CFCs Including Stem Cells

Several studies have shown that ALA, especially when combined with other metabolic therapies such as IV vitamin C can eliminate CFCs with an efficacy comparable to chemotherapy agents but without causing harm to healthy cells. These therapeutic concentrations of ALA are achievable in humans with IV administration.

ALA has been shown to inhibit growth and promote cell death in CFCs by reversing their energy metabolism closer to that of a healthy cell. CFCs prefer to produce energy by aerobic glycolysis where glucose is converted to lactate. Persistent glycolysis in CFCs and accumulating lactate create an acidic tumor microenvironment which in turn leads to reprogramming of genes for tumor progression and metastasis. ALA has been found to decrease the glycolysis of CFCs and thereby the production of lactate. This may be due to the activation of pyruvate dehydrogenase by ALA. Pyruvate dehydrogenase is an enzyme in the glycolytic pathway that converts pyruvate to acetyl CoA thus preventing lactate formation from glucose. 

A sudden shift in energy metabolism can also cause cell death in CFCs. In one study, ALA was shown to inhibit cell growth, glucose uptake, and lactate formation in CFCs, while increasing apoptosis (cell death). CFCs that do not rely on oxygen in their energy production diminish their antioxidative defenses and are therefore more sensitive and vulnerable to oxidative stress. A sudden shift towards oxidative metabolism could result in the accumulation of reactive oxygen species (ROS) and oxidative damage, leading to cell death

In another study, ALA was found to increase the sensitivity of CFCs to radiation treatment, while also preventing the formation of stem cells and metastases triggered by radiation. ALA inhibited the release of matrix metalloproteinase enzymes MMP2 and MMP9 which are responsible for degrading protein structures between cells and therefore enable CFCs to detach and migrate to distant tissues. ALA also interrupted a signaling pathway that leads to epithelial-mesenchymal transition (generation of CFC stem cells) by inactivating NF-κB. 

Read more Collapse


Biewenga GP, Haenen GR, Bast A. The pharmacology of the antioxidant lipoic acid. Gen Pharmacol. 1997 Sep;29(3):315-31. doi: 10.1016/s0306-3623(96)00474-0. PMID: 9378235.

Cao Z, Tsang M, Zhao H, Li Y. Induction of endogenous antioxidants and phase 2 enzymes by alpha-lipoic acid in rat cardiac H9C2 cells: protection against oxidative injury. Biochem Biophys Res Commun. 2003 Oct 24;310(3):979-85. doi: 10.1016/j.bbrc.2003.09.110. PMID: 14550301.

Casciari JJ, Riordan NH, Schmidt TL, Meng XL, Jackson JA, Riordan HD. Cytotoxicity of ascorbate, lipoic acid, and other antioxidants in hollow fibre in vitro tumours. Br J Cancer. 2001 Jun 1;84(11):1544-50. doi: 10.1054/bjoc.2001.1814. PMID: 11384106; PMCID: PMC2363673.

Casciato P, Ambrosi N, Caro F, Vazquez M, Müllen E, Gadano A, de Santibañes E, de Santibañes M, Zandomeni M, Chahdi M, Lazarte JC, Biagiola DA, Iaquinandi JC, Santofimia-Castaño P, Iovanna J, Incardona C, Chuluyan E. α-lipoic acid reduces postreperfusion syndrome in human liver transplantation – a pilot study. Transpl Int. 2018 Dec;31(12):1357-1368. doi: 10.1111/tri.13314. Epub 2018 Jul 20. PMID: 29974521.

Estrada DE, Ewart HS, Tsakiridis T, Volchuk A, Ramlal T, Tritschler H, Klip A. Stimulation of glucose uptake by the natural coenzyme alpha-lipoic acid/thioctic acid: participation of elements of the insulin signaling pathway. 1996 Dec;45(12):1798-804. doi: 10.2337/diab.45.12.1798. PMID: 8922368.

Feuerecker B, Pirsig S, Seidl C, Aichler M, Feuchtinger A, Bruchelt G, Senekowitsch-Schmidtke R. Lipoic acid inhibits cell proliferation of tumor cells in vitro and in vivo. Cancer Biol Ther. 2012 Dec;13(14):1425-35. doi: 10.4161/cbt.22003. Epub 2012 Sep 6. PMID: 22954700; PMCID: PMC3542233.

Ghelani H, Razmovski-Naumovski V, Pragada RR, Nammi S. (R)-α-Lipoic acid inhibits fructose-induced myoglobin fructation and the formation of advanced glycation end products (AGEs) in vitro. BMC Complement Altern Med. 2018 Jan 15;18(1):13. doi: 10.1186/s12906-017-2076-6. PMID: 29334926; PMCID: PMC5769525.

Han D, Handelman G, Marcocci L, Sen CK, Roy S, Kobuchi H, Tritschler HJ, Flohé L, Packer L. Lipoic acid increases de novo synthesis of cellular glutathione by improving cystine utilization. 1997;6(3):321-38. doi: 10.1002/biof.5520060303. PMID: 9288403.

Jariwalla RJ, Lalezari J, Cenko D, Mansour SE, Kumar A, Gangapurkar B, Nakamura D. Restoration of blood total glutathione status and lymphocyte function following alpha-lipoic acid supplementation in patients with HIV infection. J Altern Complement Med. 2008 Mar;14(2):139-46. doi: 10.1089/acm.2006.6397. PMID: 18315507.

Konrad T, Vicini P, Kusterer K, Höflich A, Assadkhani A, Böhles HJ, Sewell A, Tritschler HJ, Cobelli C, Usadel KH. alpha-Lipoic acid treatment decreases serum lactate and pyruvate concentrations and improves glucose effectiveness in lean and obese patients with type 2 diabetes. Diabetes Care. 1999 Feb;22(2):280-7. doi: 10.2337/diacare.22.2.280. PMID: 10333946.

Korotchkina LG, Sidhu S, Patel MS. R-lipoic acid inhibits mammalian pyruvate dehydrogenase kinase. Free Radic Res. 2004 Oct;38(10):1083-92. doi: 10.1080/10715760400004168. PMID: 15512796.

Lee WJ, Song KH, Koh EH, Won JC, Kim HS, Park HS, Kim MS, Kim SW, Lee KU, Park JY. Alpha-lipoic acid increases insulin sensitivity by activating AMPK in skeletal muscle. Biochem Biophys Res Commun. 2005 Jul 8;332(3):885-91. doi: 10.1016/j.bbrc.2005.05.035. PMID: 15913551.

Li BJ, Hao XY, Ren GH, Gong Y. Effect of lipoic acid combined with paclitaxel on breast cancer cells. Genet Mol Res. 2015 Dec 22;14(4):17934-40. doi: 10.4238/2015.December.22.18. PMID: 26782439.

Lin JA, Wu CH, Lu CC, Hsia SM, Yen GC. Glycative stress from advanced glycation end products (AGEs) and dicarbonyls: An emerging biological factor in cancer onset and progression. Mol Nutr Food Res. 2016 Aug;60(8):1850-64. doi: 10.1002/mnfr.201500759. Epub 2016 Feb 25. PMID: 26774083.

Mantovani G, Macciò A, Lai P, Massa E, Ghiani M, Santona MC. Cytokine activity in cancer-related anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate. Semin Oncol. 1998 Apr;25(2 Suppl 6):45-52. PMID: 9625383.

Mantovani G, Macciò A, Madeddu C, Mura L, Gramignano G, Lusso MR, Murgia V, Camboni P, Ferreli L, Mocci M, Massa E. The impact of different antioxidant agents alone or in combination on reactive oxygen species, antioxidant enzymes and cytokines in a series of advanced cancer patients at different sites: correlation with disease progression. Free Radic Res. 2003 Feb;37(2):213-23. doi: 10.1080/10715760303849. PMID: 12653210.

Mantovani G, Macciò A, Melis G, Mura L, Massa E, Mudu MC. Restoration of functional defects in peripheral blood mononuclear cells isolated from cancer patients by thiol antioxidants alpha-lipoic acid and N-acetyl cysteine. Int J Cancer. 2000 Jun 15;86(6):842-7. doi: 10.1002/(sici)1097-0215(20000615)86:6<842::aid-ijc13>;2-k. PMID: 10842199.

Mantovani G, Madeddu C, Macciò A, Gramignano G, Lusso MR, Massa E, Astara G, Serpe R. Cancer-related anorexia/cachexia syndrome and oxidative stress: an innovative approach beyond current treatment. Cancer Epidemiol Biomarkers Prev. 2004 Oct;13(10):1651-9. PMID: 15466983.

Noori N, Tabibi H, Hosseinpanah F, Hedayati M, Nafar M. Effects of combined lipoic acid and pyridoxine on albuminuria, advanced glycation end-products, and blood pressure in diabetic nephropathy. Int J Vitam Nutr Res. 2013;83(2):77-85. doi: 10.1024/0300-9831/a000147. PMID: 24491880.

Ou P, Tritschler HJ, Wolff SP. Thioctic (lipoic) acid: a therapeutic metal-chelating antioxidant? Biochem Pharmacol. 1995 Jun 29;50(1):123-6. doi: 10.1016/0006-2952(95)00116-h. PMID: 7605337.

Ramos-Gomez M, Kwak MK, Dolan PM, Itoh K, Yamamoto M, Talalay P, Kensler TW. Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3410-5. doi: 10.1073/pnas.051618798. PMID: 11248092; PMCID: PMC30667.

Scott BC, Aruoma OI, Evans PJ, O’Neill C, Van der Vliet A, Cross CE, Tritschler H, Halliwell B. Lipoic and dihydrolipoic acids as antioxidants. A critical evaluation. Free Radic Res. 1994 Feb;20(2):119-33. doi: 10.3109/10715769409147509. PMID: 7516789.

Sola S, Mir MQ, Cheema FA, Khan-Merchant N, Menon RG, Parthasarathy S, Khan BV. Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study. Circulation. 2005 Jan 25;111(3):343-8. doi: 10.1161/01.CIR.0000153272.48711.B9. Epub 2005 Jan 17. PMID: 15655130.

Spain R, Powers K, Murchison C, Heriza E, Winges K, Yadav V, Cameron M, Kim E, Horak F, Simon J, Bourdette D. Lipoic acid in secondary progressive MS: A randomized controlled pilot trial. Neurol Neuroimmunol Neuroinflamm. 2017 Jun 28;4(5):e374. doi: 10.1212/NXI.0000000000000374. PMID: 28680916; PMCID: PMC5489387.

Tripathy J, Chowdhury AR, Prusty M, Muduli K, Priyadarshini N, Reddy KS, Banerjee B, Elangovan S. α-Lipoic acid prevents the ionizing radiation-induced epithelial-mesenchymal transition and enhances the radiosensitivity in breast cancer cells. Eur J Pharmacol. 2020 Mar 15;871:172938. doi: 10.1016/j.ejphar.2020.172938. Epub 2020 Jan 17. PMID: 31958458.

Tutunchi H, Arefhosseini S, Ebrahimi-Mameghani M. Clinical effectiveness of α-lipoic acid, myo-inositol and propolis supplementation on metabolic profiles and liver function in obese patients with NAFLD: A randomized controlled clinical trial. Clin Nutr ESPEN. 2023 Apr;54:412-420. doi: 10.1016/j.clnesp.2023.02.016. Epub 2023 Feb 23. PMID: 36963888.

Wenzel U, Nickel A, Daniel H. alpha-Lipoic acid induces apoptosis in human colon cancer cells by increasing mitochondrial respiration with a concomitant O2-*-generation. Apoptosis. 2005 Mar;10(2):359-68. doi: 10.1007/s10495-005-0810-x. PMID: 15843897.

Werida RH, Elshafiey RA, Ghoneim A, Elzawawy S, Mostafa TM. Role of alpha-lipoic acid in counteracting paclitaxel- and doxorubicin-induced toxicities: a randomized controlled trial in breast cancer patients. Support Care Cancer. 2022 Sep;30(9):7281-7292. doi: 10.1007/s00520-022-07124-0. Epub 2022 May 21. PMID: 35596774; PMCID: PMC9385783.

Read more Collapse

You May Also Like

Ready To Redefine Your Views On Cancer Treatment?